The early enrollment completion in Phase 3 CSU studies is a significant derisking event, but the stock will likely trade on the Q4 2026 topline data readout rather than Q1 financials. The $345M offering caused ~18% dilution (11.9M new shares vs 66.6M outstanding), which may pressure the stock near-term. Monitor for Phase 2 PN and AD data in summer/late 2026 as additional catalysts.
CLDX drugs
CLDX drug pipeline →Price Chart
Executive Summary
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M loss (-$0.81/share) in Q1 2025, driven by increased R&D spending on barzolvolimab clinical trials and manufacturing. The key positive is the early completion of enrollment in Phase 3 CSU studies (six months ahead of schedule), with topline data expected in Q4 2026, supporting a planned BLA filing in 2027. The company also raised $345M in gross proceeds from a follow-on offering in April 2026, extending its cash runway through 2028.
Key Financial Metrics
Key Facts
- Net loss of $78.7M (-$1.18/share) for Q1 2026 vs $53.8M (-$0.81/share) in Q1 2025
- Enrollment completed six months ahead of guidance in Phase 3 CSU studies (EMBARQ-CSU1 and 2); topline data expected Q4 2026
- Raised $345M gross proceeds from April 2026 follow-on public offering (11.9M shares)
- Cash, cash equivalents and marketable securities of $451.5M at March 31, 2026; pro forma cash with offering proceeds extends runway through 2028
- R&D expenses increased to $73.0M from $52.6M YoY, driven by barzolvolimab clinical trial and manufacturing costs
- Total revenue was negligible at $15K for Q1 2026 vs $695K in Q1 2025
Financial Impact
Net loss widened by $24.9M YoY to $78.7M; cash burn of $65.6M in operating activities for Q1 2026
Risk Factors
- Phase 3 CSU topline data in Q4 2026 could fail to meet efficacy or safety endpoints
- Significant dilution from April 2026 follow-on offering (~18% share increase)
- No approved products or revenue stream; pre-commercialization stage with high cash burn
- Competition from existing CSU therapies (Xolair) and other pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003153 |
| Document: f8k_050726.htm | 0001171843-26-003153 |
| Document: 0001171843-26-003153-index-headers.html | 0001171843-26-003153 |
| Document: 0001171843-26-003153-index.html | 0001171843-26-003153 |
| Document: 0001171843-26-003153.txt | 0001171843-26-003153 |
| 8-K Data (Synthetic) | 0001171843-26-003153 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers